PPT - US Food and Drug Administration Home Page
Bevacizumab in MBC 1 Breast Cancer Take home message Sabino De Placido.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
New Strategies on Horizon Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong.
G. Cartenì Direttore U.O.S.C. di Oncologia Medica A.O.R.N. A. Cardarelli Napoli Roma, 22 febbraio 2013 Highlights in the management of renal cell carcinoma.
SUTENT® (sunitinib malate) Slide Kit
Targeted therapy for Hodgkin’s Lymphoma
Pembrolizumab in advanced melanoma
GDC-0449 in Patients With Advanced Chondrosarcomas: a French Sarcoma Group / French and US NCI phase II collaborative study Antoine Italiano, Axel Le Cesne,
Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab Presented By Raymond.
A Phase III study (EMBRACE*) of eribulin mesylate vs. treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously.
Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final.